| Document |
Document Title |
|
WO/2024/092185A1 |
Provided herein are compounds useful for treating a viral infection caused by polyomavirus, e.g., by inhibiting polyomavirus replication. Also provided are compositions and methods including the provided compounds.
|
|
WO/2024/089683A1 |
Anticancer conjugates combining a DNA methylation agent and an anticancer drug are provided herein, as well as uses of the same in cancer treatment.
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/070968A1 |
Provided are: an actinic ray-sensitive or radiation-sensitive resin composition containing (A) a resin the polarity of which is increased due to acid activity, (B) a compound which produces an acid when irradiated with actinic rays or ra...
|
|
WO/2024/060271A1 |
Provided are a characteristic impurity in an empagliflozin bulk drug or preparation and use thereof, and further provided are a detection method, a synthesis method, in-vitro pharmacological activity and in-vitro toxicity of the impurity...
|
|
WO/2024/062421A1 |
The present invention discloses polymorphs of bexagliflozin or hydraates of bexagliflozin, as crystalline solids, processes for the preparation of the polymorphs/hydrates of bexagliflozin as crystalline solids, pharmaceutical composition...
|
|
WO/2024/062310A1 |
The present invention provides derivatives of (2S,3R,4R,5S,6R)-2-[4- chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]-phenyl]-6-(
hydroxymethyl)- oxan-3,4,5-triol (empagliflozin) and (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4- ethoxybenzyl)phenyl...
|
|
WO/2024/056101A1 |
The present invention relates to a linker for an antibody-drug conjugate and a use thereof. Specifically, a linker represented by formula I is provided. An antibody-drug conjugate prepared by means of the linker are more stable and more ...
|
|
WO/2024/057998A1 |
This composition contains a compound which is expressed by formula (1), a curable compound and a solvent. The present invention also provides a film, an optical filter, a solid-state imaging element, an image display device, an infrared ...
|
|
WO/2024/053648A1 |
The present invention provides candidate molecules for constituent components of various lipid nanoparticles. The present invention pertains to a C-glycoside glycolipid compound represented by formula (I) or formula (II), a lipid nanop...
|
|
WO/2024/036812A1 |
The present invention relates to the technical field of organic synthesis, in particular to a method for preparing atorvastatin calcium. The method comprises: using 2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)acetonitr
ile as a ra...
|
|
WO/2024/040045A2 |
A genus of 2-diarylmethyl-4-aminotetrahydropyran derivatives is disclosed, which includes the following genus: The compounds activate cellular PP2A, suppress oncogenic kinase signaling and negatively regulate MYC and MYCN in cancer. The ...
|
|
WO/2024/030651A1 |
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...
|
|
WO/2024/005039A1 |
The present invention provides a method for producing a very-long-chain polyunsaturated fatty acid, the method comprising reacting a compound represented by formula II of R1-MgX1 and a compound represented by formula III of X2-(CH2)m-X i...
|
|
WO/2023/245790A1 |
The present invention relates to a method for preparing a cycloalkane from a cyclic alcohol in one step by means of a molecular sieve. The method for preparing a cycloalkane is characterized by comprising: in an inert gas atmosphere, add...
|
|
WO/2023/242100A1 |
The present invention relates to the use of compounds of formula (I) as RAS inhibitors and as a medicament, in particular for use in treating proliferative disorders, inflammatory diseases and/or genetic disorders and/or genetic disorder...
|
|
WO/2023/236809A1 |
The present invention belongs to the technical field of anti-inflammatory drugs. Disclosed are a 2,6-dibenzylidene cyclohexanone oxime compound, a method for preparing same, and use thereof. According to the present invention, a structur...
|
|
WO/2023/238718A1 |
Provided are: a difluorobutene acid amide compound having an excellent controlling effect against harmful weeds; and an herbicidal composition thereof. The herbicidal composition contains a difluorobutene acid amide compound represented ...
|
|
WO/2023/227676A1 |
The present invention relates to the use of malonic acid monoamides and malonamide esters of the formula (I) wherein the variables are as defined in the claims and the description, for controlling unwanted vegetation, to a method for com...
|
|
WO/2023/228083A1 |
The present disclosure relates to a process for the preparation of pentoxifylline intermediate. Particularly, the present disclosure relates to a process for the preparation of 6-chloro-2- hexanone. The present disclosure provides an alt...
|
|
WO/2023/225645A1 |
The present disclosure pertains to a new synthetic method for the preparation of lactones, an important class of organoleptic compounds which find use in the flavor and fragrance industries.
|
|
WO/2023/213922A1 |
The present invention primarily relates to compounds of formula (I) as defined herein. It also relates to fragrance substance mixtures as defined herein and methods for producing the same and to perfumed products as defined herein and me...
|
|
WO/2023/213035A1 |
Disclosed is a method for preparing an aryl carbon glycoside compound including a gliflozin drug, belonging to the technical field of pharmaceutical chemistry. According to the present invention, a sulfinate glycosyl donor represented by...
|
|
WO/2023/213034A1 |
Disclosed are a sulfinate glycosyl donor, a method for preparing same, and use thereof, belonging to the technical field of pharmaceutical chemistry. The present invention particularly provides a sulfinate glycosyl donor represented by f...
|
|
WO/2023/175573A1 |
The invention relates to once-a-day pharmaceutical compositions comprising a fixed dose combination of a β-blocker or a pharmaceutically acceptable salt or ester thereof and an SGLT2 inhibitor or a pharmaceutically acceptable salt or es...
|
|
WO/2023/169456A1 |
This disclosure relates to GLP-1 agonists, pharmaceutical compositions, and methods of use thereof.
|
|
WO/2023/166005A1 |
The present invention relates to the field of organic synthesis and more specifically it concerns a process for preparing compound of formula (I) from a compound of formula (II). The process to prepare compound of formula (II) and the co...
|
|
WO/2023/164219A1 |
A method of producing a polymer includes steps of providing δ-valerolactone 2-ethylidene-6-hepten-5-olide (EVL); providing an amine-containing compound; allowing the EVL and the amine-containing compound to be mixed to form a mixture; a...
|
|
WO/2023/160672A1 |
The present disclosure provides LPA antagonists of formula I, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.
|
|
WO/2023/159303A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula I or Formula II and compositions thereof for use in the treatment of cancer. In particular, the Myc- Max inhibitory compounds may be useful for the treatmen...
|
|
WO/2023/145804A1 |
The purpose of the present invention is to provide a novel B0AT1 inhibitor. The present invention relates to a compound represented by formula (I): (the symbols in the formula are as described in the description) or a salt thereof. The p...
|
|
WO/2022/187490A9 |
Provided herein are methods of ring-opening polymerization of lactones to yield bioderived polyesters with varying backbone structures.
|
|
WO/2023/138695A1 |
The present invention relates to a cathepsin K inhibitor having a structure as shown in formula (0) and/or formula (II), wherein cyanopyrimidine or a ketone serving as an electrophilic group is a key group to exert a good inhibition effe...
|
|
WO/2023/139207A1 |
The invention pertains to a process for processing a crude lactide comprising the steps of: separating a crude lactide stream comprising L-lactide, D-lactide, and meso-lactide in one or more steps to form a meso-lactide stream comprising...
|
|
WO/2023/141534A1 |
Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject i...
|
|
WO/2023/127809A1 |
In the production of agricultural and horticultural crops, etc., damages caused by pest insects, etc. are still significant, and, therefore, the development of novel pest control agents has been required due to factors such as the emerge...
|
|
WO/2023/127533A1 |
The purpose of the present invention is to provide a production method of 2-methyl-5,6-dihydro-2H-pyran, by which a high yield can be achieved even in the case of reacting at a relatively low temperature and in which the adhesion of prec...
|
|
WO/2023/116804A1 |
The present disclosure relates to a lipid compound and a lipid nanoparticle composition. Specifically, the present disclosure relates to a lipid compound, which can be used in combination with other lipid components, such as neutral lipi...
|
|
WO/2023/118968A2 |
Disclosed herein are methods of detecting xanthine oxidase expression in polycystic kidney disease, or methods of delaying the onset or treating polycystic kidney disease, or both. The inventors have made the remarkable discovery that ab...
|
|
WO/2023/115054A1 |
This application relates to methods of inhibiting the growth of human pathogenic bacteria in or on a plant by treating the seeds of the plant with an aqueous solution containing one or more ascarosides. The application also provides a me...
|
|
WO/2023/109057A1 |
Provided in the present invention is an S-configuration pro-xylane crystal form compound, which is a crystalline hydrate, and has a molecular formula of C8H16O5·H2O. Compared with the prior art, the S-configuration pro-xylane crystal fo...
|
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
|
WO/2023/114818A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/110394A1 |
The present invention is directed to a process for C-H insertion by the gem-hydrogenation of an internal alkyne.
|
|
WO/2023/114229A1 |
The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (I), including pharmaceutically acceptable salts th...
|
|
WO/2023/114819A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/109877A1 |
The present invention provides Pro-Xylane, a production method therefor, and the use thereof in cosmetics. The Pro-Xylane has a content of C-β-D-xylopyranoside-2-hydroxypropane of 95% or more, and contains C-β-D-xylopyranoside-2-(S)-hy...
|
|
WO/2023/104201A1 |
An aryl C-glucoside derivative, a preparation method therefor and the use thereof. Specifically provided are an aryl C-glucoside derivative as shown in formula I, a tautomer thereof, a stereoisomer thereof, a prodrug thereof, or a pharma...
|
|
WO/2023/102652A1 |
The present application provides compounds which are attachable to skin, in particular hydrogenated genipin compounds and de-glycosylated oleuropein compounds, which are useful, for example, as colorants and sunscreens.
|
|
WO/2023/097678A1 |
A method for synthesizing (R)-5-(2,2-dimethyl-4H-benzo[d][1,3]dioxin-6-yl)oxazolidin-2
-one. The synthesis route of the method is: where X is Br, Cl or I, preferably Br. Preferably, chiral phenyloxazolidin-2-one is prepared from a 2-brom...
|
